89bio, Inc. Made Headway
Wed, Jul 01, 2020 at 05:32 PM
89bio, Inc. (ETNB:NASDAQ) shot up at $28.17, a gain of 41.3%. On Tue 30 Jun 20, ETNB:NASDAQ hit a New 2-Week Low of $19.93. The stock got featured on our News Catalysts scanner on Thu 04 Jun 20 at 08:04 AM in the 'INVESTOR UPDATE' category. From Tue 16 Jun 20, the stock recorded 30.00% Up Days and 18.18% Green Days
The share price of the company has been moving sideways in recent weeks.
About 89bio, Inc. (ETNB:NASDAQ)
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Top 10 Gainers:
- MYOS RENS Technology Inc. (MYOS:NASDAQ), 177.27%
- Liminal BioSciences Inc. (LMNL:NASDAQ), 117.05%
- YRC Worldwide Inc. (YRCW:NASDAQ), 74.59%
- Sunworks, Inc. (SUNW:NASDAQ), 72.13%
- Martin Midstream Partners L.P. (MMLP:NASDAQ), 63.87%
- Alterity Therapeutics Limited (ATHE:NASDAQ), 57.14%
- 89bio, Inc. (ETNB:NASDAQ), 41.34%
- Akero Therapeutics, Inc. (AKRO:NASDAQ), 33.91%
- Luokung Technology Corp. (LKCO:NASDAQ), 29.55%
- Western Copper and Gold Corporation (WRN:NYSEMKT), 28.46%